Rofecoxib is a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis...

reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class. After several COX-2–inhibiting...

became the building-block for synthesis of COX-2 inhibitors. Celecoxib and rofecoxib, the first COX-2 inhibitors to reach market, were based on DuP-697. It...

complicated upper gastrointestinal events are similar between two groups. Like rofecoxib's VIGOR trial, the MEDAL Program was also criticized, this time due to...

heart attack. As a result, certain COX-2 selective inhibitors—such as rofecoxib—are no longer used due to the high risk of undiagnosed vascular disease...

(traditional NSAIDs block both versions in general). These drugs (such as rofecoxib, celecoxib, and etoricoxib) are equally effective analgesics when compared...

advice to physicians regarding celecoxib's safety. The COX-2 inhibitor rofecoxib (Vioxx) was removed from the market in 2004 due to its risk. Like all...

the dosage and its effects are comparable to human medications such as rofecoxib and piroxicam. Grapiprant has also been tested in humans, and was researched to...

double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee". Drugs. 63 (Suppl 1): 37–46. doi:10...

of increased risks of heart attacks with the selective COX-2 inhibitor rofecoxib in 2004, attention has focused on all the other members of the nonsteroidal...